A comparative study of the application of real real-world evidence to support drug approval in China and USMOHETAER Munire, WANG Su, CHEN Yu-wen1082-1088
Research on the development strategy of small and medium-sized contract development and manufacturing organization under the background of domestic pharmaceutical policy reformWU Xiao-yan, HUANG Zhe1089-1092
Considerations on constructing the team of public scientists for drug evaluationLI Feng, ZHANG Jie-ying, MAO Ning-ying1093-1097
The first drug for β-thalassemia—luspaterceptZHANG Shan-shan, XU Wen-feng, WANG Jing, XU Shuo, JIN Peng-fei1098-1101
Analytical procedure changes in the lifecycle management of biological products:regulatory consideration and case studiesLI Yi-jun, KOU Ya-zhen, WEI Kai-kun, WEI Wei1102-1108
Research progress in the production process and quality control of mRNA vaccinesTANG Qi, SHI Jin-rong, XING Pei-dong, NIE Xi-lin, YANG Xiao-ming1109-1114
Application and research progress of natamycin in fungal keratitisLIN Er-xiang, MIAO Feng, TAO Ting-lei, CHANG Yan1115-1120
Research progress on the development of drugs targeting receptors of long-chain free fatty acidsZHANG Xiao-chun, ZHAO Yan-yan, ZHANG Li-jun, LIANG Xiang-yan, ZHAO Yu-feng1121-1125
Trilaciclib in combination with immunotherapy plus chemotherapy as the first-line treatment for non-small cell lung cancer:a case-report and literature-reviewXU Hua, LI Feng, WANG Juan, ZHENG Yu, TANG Hong-qu, ZHU Yu, QIU Min, WANG Yu-hong1126-1132